Global Acute Pancreatitis Market

Acute Pancreatitis Market Size, Share, Growth Analysis, By Diagnosis(Imaging tests and Laboratory tests), By End-User(Hospitals and Clinics), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35D2197 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 59 | Figures: 75

Acute Pancreatitis Market News

  • In December 2022, Auxora is a part of Phase II clinical dose-ranging study being carried out by CalciMedica, Inc. in patients with acute pancreatitis and systemic inflammatory response syndrome.
  • In March 2022, Comparative statistics between Nafamostat and citrate anticoagulation (RCA), two separate dialysis circuit anticoagulants, were presented by AcelRx Pharmaceuticals, Inc. in paediatric patients on continuous renal replacement therapy (CRRT). A serine protease inhibitor called nafamostat is used to treat acute pancreatitis.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

The Acute Pancreatitis Market size was valued at USD 5.50 billion in 2022 and is poised to grow from USD 5.82 billion in 2023 to USD 9.21 billion by 2031, growing at a CAGR of 5.9% in the forecast period (2024-2031)

Details about each competitor are included in the competitive landscape for pancreatitis. The company's financials, revenue generated, market potential, investment in R&D, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance are among the details that are included. The statistical points mentioned here simply speak to the companies' market-related pancreatic emphasis. 'Pfizer Inc. (U.S.)', 'GlaxoSmithKline plc (U.K.)', 'Novartis AG (Switzerland)', 'Mylan N.V. (U.S.)', 'Teva Pharmaceutical Industries Ltd. (Israel)', 'Sanofi (France)', 'AstraZeneca (U.K.)', 'Johnson & Johnson Private Limited (U.S.)', 'Merck & Co., Inc. (U.S.)', 'F. Hoffmann-La Roche Ltd. (Switzerland)', 'Baxter (U.S.)', 'Bayer AG (Germany)', 'Eli Lilly and Company (U.S.)', 'Sun Pharmaceutical Industries Ltd. (India)', 'Aurobindo Pharma (India)', 'Lupin (India)', 'Allergan (Ireland)', 'AbbVie Inc. (U.S.)', 'Abbott (U.S.)', 'Bausch Health Companies Inc. (Canada)'

The market's growth rate is anticipated to be accelerated by the rising prevalence of diabetes. Cells that make insulin can be harmed by pancreatitis. The pancreas secretes the hormone insulin, which aids in controlling blood sugar levels. Nearly 45 percent of people with chronic pancreatitis develop diabetes when the disease destroys these cells. Additionally, the market for pancreatitis will grow because of an increase in elderly population and government measures to raise awareness. Along with this, shifting consumer lifestyles and expanding government-welcoming measures will accelerate market expansion. Additionally, increasing rates of obesity and pancreatic cancer will spur market expansion.

Several key market trends are shaping the landscape of the global acute pancreatitis market. Firstly, there is a growing focus on early diagnosis and intervention. Healthcare providers and researchers are placing emphasis on improving diagnostic techniques and developing tools for early detection of acute pancreatitis. This trend aims to enable prompt treatment initiation and minimize complications. Another significant trend is the increasing adoption of personalized medicine approaches. With advancements in genetic testing and molecular diagnostics, there is a growing understanding of the individual variations in the development and progression of acute pancreatitis. This knowledge is leading to the development of targeted therapies and precision medicine approaches tailored to specific patient profiles. Overall, the key market trends in the global acute pancreatitis market revolve around early diagnosis, minimally invasive interventions, personalized medicine, digital health integration, and the pursuit of novel therapeutic approaches. These trends are expected to shape the future of acute pancreatitis management, offering improved outcomes and enhanced patient care.

North America dominates the global Acute Pancreatitis market. This can be attributed to several factors, including a high prevalence of risk factors such as obesity and alcohol consumption, advanced healthcare infrastructure, and strong government initiatives promoting early diagnosis and treatment. The region is also home to several key market players, including pharmaceutical companies and medical device manufacturers, who are actively engaged in research and development activities. Furthermore, well-established reimbursement policies and a high level of awareness among healthcare professionals contribute to the dominance of North America in the acute pancreatitis market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Pancreatic Cancer Treatment Market
Buy Now GET FREE SAMPLE
Endoscopic Retrograde Cholangiopancreatography Market
Buy Now GET FREE SAMPLE
Gastroenterology Market
Buy Now GET FREE SAMPLE
Hospital-Acquired Infections Market
Buy Now GET FREE SAMPLE
Sepsis Diagnostics Market
Buy Now GET FREE SAMPLE
Non-alcoholic Steatohepatitis Biomarkers Market
Buy Now GET FREE SAMPLE
Morphine Market
Buy Now GET FREE SAMPLE
Hematology Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Acute Pancreatitis Market

Report ID: SQMIG35D2197

$5,300
BUY NOW GET FREE SAMPLE